Compare FirstEnergy Corp. (FE) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FirstEnergy Corp. vs Spyre Therapeutics Inc. Common Stock — how do they compare? FirstEnergy Corp. trades at $45.73 (market cap $26.16B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: FirstEnergy Corp. is far larger — about 3.5× Spyre Therapeutics Inc. Common Stock's market cap, and FirstEnergy Corp. pays a 4.11% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold FirstEnergy Corp. for 72 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| FE | SYRE | |
|---|---|---|
Market Cap | $26.16B | $7.52B |
Volume | 4,932,658 | 1,441,031 |
Sector | Utilities | Health |
52-Week High | $51.91 | $108.92 |
52-Week Low | $43.04 | $22.18 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $55.08B | $6.52B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $45.41, up 0.11% with a bullish technical signal. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing. Revenue grew to $15.09B in 2025 with a 6.86% net margin. Analyst consensus is Moderate Buy with a $51.00 price target, representing 12.3% upside. Recent developments include the Energize365 investment plan and consistent dividend payments.
FirstEnergy presents a stable utility investment with moderate growth potential through infrastructure investments. Key opportunities include the $36B Energize365 plan and rising data-center demand. Risks include high debt levels ($24.03B total debt), interest rate sensitivity, and regulatory challenges. The stock offers income through dividends but faces execution risks on capital projects.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About FirstEnergy Corp.
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
